Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response (CR) or partial response (PR) with " three abnormal skeletal areas on iodine 123-metaiodobenzylguanidine ([123I]mIBG) scintigraphy and no bone marrow disease proceed to high dose therapy (HDT). In this study, topotecan-vincristine-doxorubicin (TVD) was evaluated in patients failing to achieve these criteria, with the aim of improving the metastatic response rate. Materials and Methods Patients with metastatic high-risk neuroblastoma who had not achieved the SIOPEN criteria for HDT after induction received two courses of topotecan 1.5 mg/m2/day for 5 days, followed by a 48-hour infusion of vincristine, 2 mg/m2, and doxorubicin, 45 mg/m2. Results Sixty-three patients were eligible and evaluable. Following two courses of TVD, four (6.4%) patients had an overall CR, while 28 (44.4%) had a PR with a combined response rate of 50.8% (95% confidence interval [CI], 37.9 to 63.6). Of these, 23 patients achieved a metastatic CR or a PR with " 3 mIBG skeletal areas and no bone marrow disease (36.5%; 95% CI, 24.7 to 49.6) and were eligible to receive HDT. Toxicity was mostly haematological, affecting 106 of the 126 courses (84.1%; 95% CI, 76.5 to 90.0), and dose reduction was necessary in six patients. Stomatitis was the second most common nonhematological toxicity, occurring in 20 patients (31.7%). Conclusion TVD was effective in improving the response rate of high-risk neuroblastoma patients after induction with COJEC enabling them to proceed to HDT. However, the long-term benefits of TVD needs to be determined in randomized clinical trials.
Abstract
Purpose Metastatic response to induction therapy for high-risk neuroblastoma is a prognostic factor. In the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) HR-NBL-1 protocol, only patients with metastatic complete response (CR) or partial response (PR) with " three abnormal skeletal areas on iodine 123-metaiodobenzylguanidine ([123I]mIBG) scintigraphy and no bone marrow disease proceed to high dose therapy (HDT). In this study, topotecan-vincristine-doxorubicin (TVD) was evaluated in patients failing to achieve these criteria, with the aim of improving the metastatic response rate. Materials and Methods Patients with metastatic high-risk neuroblastoma who had not achieved the SIOPEN criteria for HDT after induction received two courses of topotecan 1.5 mg/m2/day for 5 days, followed by a 48-hour infusion of vincristine, 2 mg/m2, and doxorubicin, 45 mg/m2. Results Sixty-three patients were eligible and evaluable. Following two courses of TVD, four (6.4%) patients had an overall CR, while 28 (44.4%) had a PR with a combined response rate of 50.8% (95% confidence interval [CI], 37.9 to 63.6). Of these, 23 patients achieved a metastatic CR or a PR with " 3 mIBG skeletal areas and no bone marrow disease (36.5%; 95% CI, 24.7 to 49.6) and were eligible to receive HDT. Toxicity was mostly haematological, affecting 106 of the 126 courses (84.1%; 95% CI, 76.5 to 90.0), and dose reduction was necessary in six patients. Stomatitis was the second most common nonhematological toxicity, occurring in 20 patients (31.7%). Conclusion TVD was effective in improving the response rate of high-risk neuroblastoma patients after induction with COJEC enabling them to proceed to HDT. However, the long-term benefits of TVD needs to be determined in randomized clinical trials.
참고문헌 (25)
- Haupt R, "Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry", J Clin Oncol, 28, pp.2331~2338 (2010)[DOI]
- Kreissman SG, "Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial", Lancet Oncol, 14, pp.999~1008 (2013)[DOI]
- Pearson AD, "High-dose rapid and standard induction chemo-therapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial", Lancet Oncol, 9, pp.247~256 (2008)[DOI]
- Ladenstein R, "Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1", SIOPEN study, 2010, pp.28, 3516~3524
- Ladenstein R, "28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures", Bone Marrow Transplant, 41(Suppl 2), pp.S118~S127 (2008)[DOI]
- Decarolis B, "Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study", J Clin Oncol, 31, pp.944~951 (2013)[DOI]
- Yanik GA, "Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group", J Nucl Med, 54, pp.541~548 (2013)[DOI]
- Garaventa A, "A phase II study of topotecan with vincristine and doxorubicin in children with recurrent", refractory neuroblastoma, 2003, pp.98, 2488~2494
- Brodeur GM, "Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment", J Clin Oncol, 11, pp.1466~1477 (1993)[DOI]
- Castagnola E, "Prophylaxis and empirical therapy of infection in cancer patients;Mandell, Douglas, and Bennett's principles and practice of infectious diseases", pp.3395~3413 (2015), Elsevier
- Simon R, "Optimal two-stage designs for phase II clinical trials", Control Clin Trials, 10, pp.1~10 (1989)[DOI]
- Kim JH, "Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I", Int J Radiat Oncol Biol Phys, 22, pp.515~518 (1992)[DOI]
- Rowinsky EK, "Review of phase I clinical studies with topotecan", Semin Oncol, 24(6 Suppl 20), pp.S20~ (1997)
- Thompson J, "Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts", Clin Cancer Res, 5, pp.3617~3631 (1999)
- Vassal G, "DNA-topoisomerase I, a new target for the treatment of neuroblastoma", Eur J Cancer, 33, pp.2011~2015 (1997)[DOI]
- Pratt CB, "Phase I study of topotecan for pediatric patients with malignant solid tumors", J Clin Oncol, 12, pp.539~543 (1994)[DOI]
- Blaney SM, "Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study", Clin Cancer Res, 4, pp.357~360 (1998)
- Santana VM, "Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach", J Clin Oncol, 23, pp.4039~4047 (2005)[DOI]
- London WB, "Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study", J Clin Oncol, 28, pp.3808~3815 (2010)[DOI]
- Saylors RL 3rd, "Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study", J Clin Oncol, 19, pp.3463~3469 (2001)[DOI]
- Rubie H, "Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours", Eur J Cancer, 46, pp.2763~2770 (2010)[DOI]
- Di Giannatale A, "Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study", Eur J Cancer, 50, pp.170~177 (2014)
- Simon T, "Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial", J Cancer Res Clin Oncol, 133, pp.653~661 (2007)[DOI]
- Kretschmar CS, "Response to paclitaxel, topotecan, and topotecancyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study", J Clin Oncol, 22, pp.4119~4126 (2004)[DOI]
- Park JR, "Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study", J Clin Oncol, 29, pp.4351~4357 (2011)[DOI]